Trulicity (Dulaglutide) for Adolescents Ages 12 to 17: School and Activity Considerations

Why Trulicity Is Prescribed for Teens With Type 2 Diabetes

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates glucose-dependent insulin secretion and suppresses glucagon, slowing gastric emptying. The FDA approved its use in patients as young as 10 years old in June 2020, making it one of the few GLP-1 agents with a pediatric indication for type 2 diabetes. Adolescent type 2 diabetes differs from the adult form in that it tends to be more aggressive, with faster beta-cell decline, making earlier pharmacologic intervention important.

The AWARD-PEDS Trial

The foundational evidence comes from AWARD-PEDS (NCT02961374), a 26-week randomized, double-blind, placebo-controlled trial. Published in the New England Journal of Medicine in 2020, it enrolled 154 participants ages 10 to 17 with type 2 diabetes. Dulaglutide 0.75 mg and 1.5 mg both outperformed placebo on HbA1c reduction. The 0.75 mg group achieved a mean HbA1c change of -0.6 percentage points versus +0.5 percentage points for placebo (P<0.001). The 1.5 mg group showed a mean change of -0.9 percentage points (P<0.001). Body weight differences between dulaglutide and placebo groups were not statistically significant at 26 weeks.

How Once-Weekly Dosing Shapes Daily School Life

The weekly injection schedule is one of the most school-friendly features of this drug. Unlike insulin, which may require multiple daily injections or carbohydrate-counting boluses at lunch, dulaglutide is injected once per week at home. A teen can inject on Sunday morning and never need to carry a syringe to class. This removes the need to visit the school nurse for a midday injection on most school days, though the nurse's office should still be informed and prepared. The American Diabetes Association's 2024 Standards of Care in Diabetes recommends that all students with diabetes have a Diabetes Medical Management Plan (DMMP) on file regardless of medication type.

Managing Side Effects During the School Day

GI symptoms are the most clinically relevant side effects for school-age adolescents on dulaglutide. In AWARD-PEDS, nausea was reported in approximately 17% of the 1.5 mg group, and vomiting in about 16%, compared with lower rates in the placebo group. These rates were highest during the first 4 weeks of treatment and generally diminished over time.

Nausea and Vomiting

A teen who just started Trulicity may experience waves of nausea during the first few weeks, including on school days. Practical strategies include:

• Timing the weekly injection for a Friday evening so the peak of early GI discomfort falls on a weekend
• Eating smaller portions at school lunch rather than a full meal
• Avoiding high-fat or high-sugar cafeteria foods, which can worsen gastric-emptying-related nausea
• Keeping a small snack of plain crackers or dry toast in a locker for mild nausea relief

The school nurse should be aware of GI symptoms so they can distinguish medication-related nausea from illness. A student vomiting due to dulaglutide initiation does not necessarily need to go home or to the emergency room, unless symptoms are severe or accompanied by signs of dehydration.

Diarrhea and Bathroom Access

Diarrhea affected approximately 10 to 12% of adolescents in the GLP-1 arm of AWARD-PEDS during the early titration period. Teachers and administrators should be informed (with the student's consent or parents' written authorization) that the student may need unscheduled restroom access. A brief note from the prescribing clinician documenting this need is generally sufficient to satisfy school accommodation requests under Section 504 of the Rehabilitation Act.

When to Contact the Medical Team

Parents and students should contact the prescribing clinician if vomiting or diarrhea persists beyond 7 days without improvement, if the student cannot keep liquids down, or if blood glucose readings rise unexpectedly during a GI illness. Significant dehydration can impair renal function and alter drug clearance. The FDA prescribing information for Trulicity lists severe gastrointestinal disease as a precaution, and clinicians should be contacted promptly in those cases.

Hypoglycemia: Risk Stratification for Active Teens

As a monotherapy, dulaglutide carries a low intrinsic risk of hypoglycemia because it stimulates insulin secretion only when glucose levels are elevated. In AWARD-PEDS, documented symptomatic hypoglycemia in the dulaglutide arms was infrequent as a standalone finding. However, many adolescents with type 2 diabetes also use metformin, and some may be co-prescribed insulin or a sulfonylurea. That combination changes the risk profile significantly.

Hypoglycemia During Physical Education and Sports

Physical activity lowers blood glucose through glucose uptake by contracting muscle tissue independent of insulin signaling. An adolescent taking dulaglutide plus a sulfonylurea or insulin who then runs a 30-minute PE class may experience blood glucose drops that would not occur at rest. The ADA's 2024 Standards of Care recommend that students with diabetes on insulin or insulin secretagogues check blood glucose before, during (for activity over 30 minutes), and after vigorous exercise.

For teens on dulaglutide alone or with only metformin, routine glucose monitoring around PE class is generally not required by clinical guidelines, though it remains at the prescriber's discretion based on individual patient factors.

Recognizing Hypoglycemia Symptoms

Coaches, PE teachers, and school nurses should know the signs: shakiness, sweating, pallor, confusion, irritability, and difficulty concentrating. The school's emergency action plan should include access to 15 to 20 g of fast-acting carbohydrate (glucose tablets, 4 oz of juice, or regular soda) and a glucagon emergency kit if the student is on insulin combination therapy. Glucagon kits, including intranasal glucagon (Baqsimi) and injectable kits, should be stored per manufacturer guidance and checked for expiration at the start of each school year.

Blood Glucose Targets for Adolescents

The Endocrine Society's Clinical Practice Guideline on Type 2 Diabetes in Youth recommends an HbA1c target of <7% for most adolescents without frequent hypoglycemia. Pre-exercise glucose targets for teens on insulin combinations are generally 126 to 180 mg/dL; for those on GLP-1 monotherapy, the exercise-specific target range is less rigidly defined, and clinical judgment applies.

Pen Storage, Handling, and Injection Logistics at School

The Trulicity autoinjector pen contains a single dose and is pre-filled. The injection is subcutaneous, using a hidden needle, which can reduce anxiety for needle-phobic teenagers. However, storage and handling at school require coordination.

Temperature Storage Rules

According to the Trulicity FDA label, unused pens should be refrigerated at 36 to 46°F (2 to 8°C). Once removed from the refrigerator, a pen can be kept at room temperature (up to 77°F or 25°C) for up to 14 days. Most adolescents will not need to bring an injection pen to school at all, given the once-weekly schedule. If a student needs to inject during school hours due to scheduling, the pen should be stored in the nurse's office refrigerator, not in a gym locker or backpack where temperatures fluctuate.

Self-Injection Competency

The FDA's approval of dulaglutide in adolescents assumed that injections would be administered by or under the supervision of a healthcare provider or trained caregiver. However, many 14 to 17-year-olds are trained to self-inject. The diabetes care team should confirm self-injection competency before a teen is expected to inject at school independently. A demonstration checklist, reviewed and signed at a clinic visit, is a practical documentation method.

Section 504 Accommodations for Diabetes Management

Under Section 504 of the Rehabilitation Act, students with diabetes are entitled to reasonable accommodations in school. These may include permission to carry glucose monitoring supplies, access to snacks, unscheduled restroom access, and, if needed, permission to self-administer medication. A CDC resource on diabetes management in schools outlines these rights. Parents should request a 504 meeting with the school at the start of treatment and update the plan if the medication regimen changes.

Physical Activity and Sports Participation

Exercise is a cornerstone of type 2 diabetes management in youth. The ADA 2024 Standards recommend that children and adolescents with type 2 diabetes achieve at least 60 minutes of moderate-to-vigorous physical activity daily. Dulaglutide does not contraindicate any form of exercise, and there is no direct pharmacokinetic interaction between GLP-1 receptor agonism and aerobic or resistance training.

Team Sports and Competitive Athletics

Adolescents taking Trulicity can participate in team sports, competitive athletics, and endurance events. The once-weekly injection does not need to be timed around game days or practices. GI side effects, if they persist beyond the initial titration period, are unusual during strenuous exercise and are more commonly associated with eating patterns than with exertion. If a student-athlete notices increased nausea during heavy training weeks, a dietary review (looking at meal size and composition around training) is the first step before attributing symptoms to medication.

Resistance Training and Muscle Preservation

GLP-1 receptor agonists have been associated with modest reductions in lean body mass in adults during weight loss phases, as shown in the STEP-1 trial (N=1,961) for semaglutide, a related GLP-1 agent. The lean mass data for dulaglutide in adolescents specifically is limited, since AWARD-PEDS was not powered to detect body composition changes. Clinicians monitoring adolescent athletes on dulaglutide should consider periodic assessment of lean mass if weight loss is substantial, and encourage adequate protein intake (at least 1.2 to 1.6 g/kg/day for active teens) alongside resistance training to support muscle health.

Hydration and GI Symptoms During Activity

Teens experiencing GI side effects should be especially attentive to hydration during physical activity. Vomiting and diarrhea increase fluid losses, and exercise adds to that deficit. Coaches should allow water breaks on demand for students with documented gastrointestinal conditions. Electrolyte replacement drinks may be useful during prolonged training in teens with active GI symptoms, though sugar content should be factored into glucose management if the student is on a sulfonylurea or insulin.

Communicating With the School Health Team

Effective diabetes management at school requires clear communication between the prescribing clinician, the family, and the school health staff.

The Diabetes Medical Management Plan

The DMMP is a written document completed by the healthcare provider that specifies the student's diabetes regimen, medication doses, blood glucose targets, hypoglycemia protocols, and emergency contacts. The American Diabetes Association recommends that every student with diabetes have an updated DMMP at the start of each school year and whenever the treatment plan changes. Adding dulaglutide to a student's regimen should trigger an updated DMMP.

What the School Nurse Needs to Know About Dulaglutide

The school nurse should understand:

• Dulaglutide is injected once per week, almost never during school hours
• The drug itself does not cause hypoglycemia as a standalone agent
• GI symptoms during the first month of therapy are expected and usually self-limiting
• The student may need restroom access during peak GI periods
• If a student appears ill after a recent dose change, nausea or vomiting should be considered before assuming infectious illness

A brief written medication summary from the prescribing clinician, no longer than one page, covers these points efficiently. Nurses are not expected to administer this medication in routine school settings, but they should be equipped to respond if a student reports side effects.

Talking With Teachers and Coaches

Teenagers often prefer not to disclose a diabetes diagnosis broadly. The student and family should decide together which school staff members are informed. At minimum, the nurse and one designated administrator should know. Coaches overseeing athletic programs should be aware if there is any hypoglycemia risk (such as combination therapy with insulin), and a basic hypoglycemia response protocol should be posted in the athletic training room.

The following framework summarizes the key school-day decision points for adolescents on dulaglutide, intended for clinical teams to review with patients and families at the time of prescription:

HealthRX School Readiness Framework for Adolescents Starting Dulaglutide

1. Confirm injection timing (home-based, weekly; select a weekend day to minimize school-day GI impact)
2. Update or create DMMP before the first school day on the new regimen
3. Assess hypoglycemia risk: is dulaglutide being used alone, with metformin only, or with insulin/sulfonylurea? Protocol differs by combination.
4. Arrange refrigerator access in nurse's office if any school-day injections are anticipated
5. Brief the school nurse on expected GI side effects and their timeline (4-week peak)
6. Confirm self-injection competency if the student is expected to self-administer
7. Request 504 accommodations if not already in place
8. Reassess the plan at the 4-week and 12-week follow-up visits

Monitoring and Follow-Up Across the School Year

The Endocrine Society's 2023 guideline on type 2 diabetes in youth recommends HbA1c measurement every 3 months during the first year of treatment for adolescents with type 2 diabetes. Scheduling these visits around school vacations or after-school hours improves adherence for active students. If HbA1c remains above target at 3 months on 0.75 mg, the clinician may titrate to 1.5 mg weekly; this dose escalation may trigger a brief recurrence of GI symptoms, so the school plan should be reviewed again at that visit.

Lipid panels, blood pressure, and urine albumin-to-creatinine ratio should be checked annually per ADA 2024 Standards. These are lab visits, not school-day events, but a clinician who coordinates with the school calendar helps families avoid missing both school and work unnecessarily. Most adolescents on dulaglutide who tolerate the medication well should experience no disruption to normal school attendance, extracurricular activities, or athletic participation by month 2 of treatment.